|
Jan 19
|
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
|
|
Jan 9
|
4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares
|
|
Jan 6
|
Andreas Halvorsen Adjusts Position in 4D Molecular Therapeutics Inc
|
|
Jan 4
|
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
|
|
Jan 3
|
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
|
|
Dec 21
|
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
|
|
Dec 4
|
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
|
|
Nov 14
|
Broker Revenue Forecasts For 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Are Surging Higher
|
|
Nov 12
|
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
|
Nov 9
|
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
|
|
Nov 1
|
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
|
|
Jul 17
|
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
|
|
Jun 8
|
4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why
|
|
Jun 7
|
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
|
|
Apr 27
|
What's Going On With 4D Molecular Therapeutics Stock Today
|
|
Apr 27
|
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
|
|
Apr 24
|
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
|
|
Apr 24
|
4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
|